【摘 要】
：
Antibodies have rapidly become a mainstay of therapeutics.The bispecific antibody (bsAb) field has evolved over the past two decades mainly for applications that cannot be easily achieved by monospeci
【机 构】
：
Principal Research Scientist Abbott Bioresearch Center USA
论文部分内容阅读
Antibodies have rapidly become a mainstay of therapeutics.The bispecific antibody (bsAb) field has evolved over the past two decades mainly for applications that cannot be easily achieved by monospecific mAbs, such as re-directed toxicity.New developments in the antibody engineering field have significantly improved low expression, molecule heterogeneity, poor solubility and stability, disappointing efficacy, severe side effects and immunogenicity observed in clinical trials associated with early failures.
其他文献
The templatisation of the MAb purification process using scalable technologies has been instrumental in speeding up process development.However, one of the key bottlenecks to producing clinical materi
A robust and scalable purification process was developed to quickly generate antibody of high purity and sufficient quantity from glycoengineered Pichia pastoris fermentation.Protein A affinity chroma
Modem production technologies and novel facility design philosophies have the potential to revolutionize the business case for MAb development and production facilities.Bringing MAb products from deve
This presentation looks at the design of a new facility dedicated to streamline production of MAb clinical supply in close proximity of our existing R & D center.From initial concept to construction,
A proof of concept study is presented demonstrating the potential of small molecule affinity ligands as a qualitative and economic alternative to Protein A for the purification of monoclonal antibodie
Periostin (PN), an extracellular matrix protein, is reported to be overexpressed in a variety of human cancers and its functions appear to be linked to tumor angiogenesis and metastasis.Our previous r
The identification of peptide epitopes with techniques such as phage display peptide libraries has opened the opportunity to develop specific targeting molecules for a variety of antibody-based biomed
The presentation will provide an overview of the U.S.Food and Drug Administration (FDA) approval process for follow-on biologics under the new U.S.healthcare law; the doctrine of Patent Misuse in the
Molecular Biology is a disruptive technology in the pharmaceutical industry, roiling the established order, creating new paradigms for drug discovery and development, and ultimately for medicine itsel
Approved and investigational therapeutic monoclonal antibodies (mAbs) represent the leading sector of the biopharmaceuticals market and research.However, pursuing mAb affinity and structural similarit